Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
- PMID: 17895470
- DOI: 10.1093/jnci/djm167
Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Comment on
-
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61. doi: 10.1093/jnci/djm158. Epub 2007 Sep 25. J Natl Cancer Inst. 2007. PMID: 17895472
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
